<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03124576</url>
  </required_header>
  <id_info>
    <org_study_id>NL56796.068.16</org_study_id>
    <nct_id>NCT03124576</nct_id>
  </id_info>
  <brief_title>Reappraisal of Atrial Fibrillation: RACE-V - Work Package 5</brief_title>
  <acronym>RACE V- WP 5</acronym>
  <official_title>Reappraisal of Atrial Fibrillation: Interaction Between HyperCoagulability, Electrical Remodeling, and Vascular Destabilisation in the Progression of AF- The Tissue Bank Project</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Academisch Ziekenhuis Maastricht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Academisch Ziekenhuis Maastricht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the proposed study the investigators aim to clarify the relative contribution of these&#xD;
      different mechanisms to the progression of atrial fibrillation (AF). Also the contribution of&#xD;
      the individual genetic background will be investigated. Furthermore, the investigators aim to&#xD;
      identify clinical parameters and biomarkers informing on the main mechanisms of AF&#xD;
      progression in atrial tissue.&#xD;
&#xD;
      For this purpose, in all included patients atrial biopsies will be taken during cardiac&#xD;
      surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      An estimated 380 patients will be included&#xD;
&#xD;
      Four patient categories will be included enabling to study patients with different stages of&#xD;
      AF progression;&#xD;
&#xD;
        1. Patients without history of atrial fibrillation, without new onset atrial fibrillation&#xD;
           detected by continuous rhythm monitoring after surgery (control group),&#xD;
&#xD;
        2. Patients without history of atrial fibrillation, with new onset atrial fibrillation&#xD;
           detected by continuous rhythm monitoring,&#xD;
&#xD;
        3. Patients with self-terminating atrial fibrillation at inclusion, and&#xD;
&#xD;
        4. Patients with non-self-terminating atrial fibrillation at inclusion. At baseline&#xD;
           in-depth phenotyping and genotyping will be performed. Continuous rhythm monitoring will&#xD;
           also be performed in all patients. The combination of extensive phenotyping, genotyping&#xD;
           and atrial fibrillation burden follow-up offers the unique opportunity to study the&#xD;
           atrial tissue alterations and atrial gene expression changes in different stages of&#xD;
           atrial fibrillation progression and to correlate these data to the phenotype of the&#xD;
           patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biochemical factors in atrial biopsies and blood samples</measure>
    <time_frame>2.5 year follow up</time_frame>
    <description>Biochemical factors in atrial biopsies and blood samples associated with atrial fibrillation and contributing to atrial fibrillation progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Molecular factors in atrial biopsies and blood samples</measure>
    <time_frame>2.5 year follow up</time_frame>
    <description>Molecular factors in atrial biopsies and blood samples associated with atrial fibrillation and contributing to atrial fibrillation progression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Genetic factors in atrial biopsies and blood samples</measure>
    <time_frame>2.5 year follow up</time_frame>
    <description>Genetic factors in atrial biopsies and blood samples associated with atrial fibrillation and contributing to atrial fibrillation progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atrial fibrillation burden</measure>
    <time_frame>2.5 year follow up</time_frame>
    <description>Atrial fibrillation burden</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of atrial fibrillation episodes</measure>
    <time_frame>2.5 year follow up</time_frame>
    <description>Number of atrial fibrillation episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of atrial fibrillation episodes</measure>
    <time_frame>2.5 year follow up</time_frame>
    <description>Duration of atrial fibrillation episodes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiovascular and cerebrovascular events</measure>
    <time_frame>2.5 year follow up</time_frame>
    <description>Major adverse cardiovascular and cerebrovascular events (i.e. death, stroke, myocardial infarction)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>First recurrent atrial fibrillation;</measure>
    <time_frame>2.5 year follow up</time_frame>
    <description>First recurrent atrial fibrillation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF progression</measure>
    <time_frame>2.5 year follow up</time_frame>
    <description>Self-terminating atrial fibrillation turning into non-self-terminating atrial fibrillation measured from ECGs and implantable loop recorders</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF complexity</measure>
    <time_frame>2.5 year follow up</time_frame>
    <description>Electrical atrial fibrillation complexity or signs of atrial conduction disturbances measured from ECGs</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">380</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>Without history of atrial fibrillation/without newly developed atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group B</arm_group_label>
    <description>Patients without history of atrial fibrillation, with new onset atrial fibrillation detected by continuous rhythm monitoring with a an Implantable loop recorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group C</arm_group_label>
    <description>Patients with self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group D</arm_group_label>
    <description>Patients with non-self-terminating atrial fibrillation at inclusion Implantable loop recorder is used for continuous rhythm monitoring</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable loop recorder</intervention_name>
    <description>Continuous rhythm monitoring Medtronic</description>
    <arm_group_label>control group</arm_group_label>
    <arm_group_label>group B</arm_group_label>
    <arm_group_label>group C</arm_group_label>
    <arm_group_label>group D</arm_group_label>
    <other_name>Reveal LINQ™,Medtronic</other_name>
    <other_name>ConfirmTM, St. Jude</other_name>
    <other_name>BiomonitorTM, Biotronik</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      atrial tissue samples, whole blood&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        380 patiënts undergoing elective open chest heart surgery.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 years;&#xD;
&#xD;
          -  Undergoing first elective open chest cardiac surgery or surgical ablation for atrial&#xD;
             fibrillation;&#xD;
&#xD;
          -  Able and willing to sign informed consent for the registry;&#xD;
&#xD;
          -  Able and willing to undergo implantation of implantable loop recorder (unless the&#xD;
             patients has a pacemaker or implantable cardioverter-defibrillator (ICD) with atrial&#xD;
             leads)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  • Deemed unsuitable or not willing to undergo implantation of implantable loop&#xD;
             recorder or attend follow-up visits.&#xD;
&#xD;
               -  Pregnancy.&#xD;
&#xD;
               -  Life expectancy of less than 2.5 years.&#xD;
&#xD;
               -  History of prior cardiac surgery or ablation for atrial fibrillation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jos Maessen, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Academisch Ziekenhuis Maastricht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martijn Gilbers, Drs.</last_name>
    <phone>0031620606559</phone>
    <email>M.Gilbers@maastrichtuniversity.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>AZMaastricht</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martijn Gilbers, Drs</last_name>
      <phone>0031620606559</phone>
      <email>martijn.gilbers@mumc.nl</email>
    </contact>
    <contact_backup>
      <last_name>Elham Bidar, Drs</last_name>
      <phone>0031624266586</phone>
      <email>elham.bidar@mumc.nl</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>November 1, 2016</study_first_submitted>
  <study_first_submitted_qc>April 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 24, 2017</study_first_posted>
  <last_update_submitted>July 18, 2018</last_update_submitted>
  <last_update_submitted_qc>July 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Academisch Ziekenhuis Maastricht</investigator_affiliation>
    <investigator_full_name>J. G. Maessen</investigator_full_name>
    <investigator_title>Prof. Dr.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

